Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Phase 2

Terminated

Conditions: Renal Transplant

Interventions: Drug: Belatacept
Drug: Sirolimus
Drug: Anti-thymocyte globulin
Drug: methylprednisolone

First Posted Date: 2006-06-29

Last Posted Date: 2017-04-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT00346151

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase 2

Completed

Conditions: Peritoneal Neoplasms
Intestinal Obstruction
Carcinomatosis

Interventions: Drug: Octreotide LAR
Drug: Octreotide (Immediate release)
Drug: Placebo
Drug: methylprednisolone

First Posted Date: 2006-06-02

Last Posted Date: 2011-09-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00332696

Locations: 🇫🇷
Novartis Investigative Site, Creteil, France

Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy

Phase 3

Completed

Conditions: Hemangiomas

First Posted Date: 2006-04-10

Last Posted Date: 2018-04-19

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 20

Registration Number: NCT00312520

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Childhood Myelodysplastic Syndromes
Chronic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Disseminated Neuroblastoma
Juvenile Myelomonocytic Leukemia

Interventions: Biological: etanercept
Drug: methylprednisolone

First Posted Date: 2006-04-03

Last Posted Date: 2017-09-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 39

Registration Number: NCT00309907

Locations: 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 23 locations

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Phase 2

Withdrawn

Conditions: AIDS-related Lymphoma
Adult Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma

First Posted Date: 2006-04-03

Last Posted Date: 2016-02-03

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT00310128

Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)

Phase 3

Completed

Conditions: Kidney Diseases

Interventions: Drug: methylprednisolone

First Posted Date: 2006-03-31

Last Posted Date: 2015-04-23

Lead Sponsor: Klinik für Kinder- und Jugendmedizin

Target Recruit Count: 42

Registration Number: NCT00309218

Locations: 🇩🇪
University Children's Hospital, Heidelberg, Germany

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Phase 2

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Severe Congenital Neutropenia
Diamond-blackfan Anemia
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: alemtuzumab
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: methylprednisolone
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-13

Last Posted Date: 2017-09-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00301834

Locations: 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States